



Cite this: *Chem. Sci.*, 2024, **15**, 19858

All publication charges for this article have been paid for by the Royal Society of Chemistry

Analysis of the cryptic biosynthetic gene cluster encoding the RiPP curacozole reveals a phenylalanine-specific peptide hydroxylase†

Samantha Hollands,^{‡,a} Julia Tasch,^{‡,b} David J. Simon,^a Dimah Wassouf,^b Isobel Barber,^a Arne Gessner,^{bc} Andreas Bechthold ^b and David L. Zechel ^{*,a}

Curacozole is representative of a cyanobactin-like sub-family of ribosomally synthesized and post-translationally modified peptides (RiPPs). The molecule is distinguished by its small macrocyclic structure, a poly-azole sequence that includes a phenyloxazole moiety, and a *D-allo*-Ile residue. The enzymatic steps required for its formation are not well understood. The predicted biosynthetic gene cluster (BGC) for curacozole in *Streptomyces curacoi* is cryptic, but is shown to be potently activated upon constitutive expression of the *bldA*-specified Leu-tRNA(UUA) molecule. Heterologous expression and gene deletion studies have defined the minimum BGC as consisting of seven genes, *czlA*, *D*, *E*, *B1*, *C1*, *F*, and *BC*. The biosynthetic pathway is highly substrate tolerant, accepting six variants of the precursor peptide *CzlA* to form new curacozole derivatives. This includes replacing the phenyloxazole moiety of curacozole with indole and *p*-hydroxyphenyloxazole groups by conversion of the corresponding *CzlA* Phe18Trp and Phe18Tyr variants. *In vitro* experiments with purified enzymes demonstrate that *CzlD* and *CzlBC* perform cyclodehydration and dehydrogenation reactions, respectively, to form a single oxazole from Ser 22 of *CzlA*. The curacozole BGC is flanked by *czlI*, a non-essential but conserved gene of unknown function. *In vitro* studies demonstrate *CzlI* to be a non-heme iron(II) and 2-oxoglutarate-dependent dioxygenase, catalyzing the hydroxylation of Phe18 on *CzlA* to form the *CzlA* Phe18Tyr variant, which is then processed to form the *p*-hydroxyphenyloxazole derivative of curacozole. Overall, this work highlights the amenability of RiPP biosynthesis for engineering the production of new compounds and adds to the repertoire of known RiPP enzymes.

Received 5th April 2024
Accepted 4th November 2024

DOI: 10.1039/d4sc02262a
rsc.li/chemical-science

Introduction

Curacozole (**1**) is a cytotoxic cyanobactin-like molecule that was recently isolated from a mutant strain of *Streptomyces curacoi*.¹ Cyanobactins are a large and structurally diverse class of ribosomally synthesized and post-translationally modified peptides (RiPPs)^{2–5} where **1** represents a biosynthetically distinct sub-family that includes aurantizolicin (**2**),⁶ YM-216391 (**3**),⁷ urukthapelstatin (**4**),⁸ and mechercharmycin⁹ (renamed

mechercharstatin,¹⁰ **5**) (Fig. 1A). These compounds share a macrocyclic structure derived from eight amino acids, a poly-azole sequence that includes a unique phenyloxazole, and a conserved *D-allo*-Ile residue.¹¹ **4** and **5** are further distinguished by dehydroalanine and dehydrobutyryne residues, respectively. The sequentially linked oxazoles and thiazoles in these compounds are reminiscent of the cyanobactin and telomerase inhibitor, telomestatin (**6**).¹² The BGC encoding **1** (*czl*)¹ is highly conserved with those encoding **2** (*aur*)⁶ and **3** (*ym*),¹³ reflecting their highly similar structures (Fig. 1B). Interestingly, *czl* in *S. curacoi* does not appear to be expressed under standard cultivation conditions,⁶ which inspired Kaweewan and co-workers to select rifampicin-resistant mutants of this strain in order to induce production of **1**.¹ Compounds **1** through **5** exhibit strong anticancer activity, analogous to **6**, but do not appear to target telomerase as a mode of action.⁸

The basic principles of cyanobactin biosynthesis are best understood for the patellamide (*pat*) and trunkamide (*tru*) pathways.^{3,14–16} Using nomenclature for the *pat* pathway, biosynthesis begins with a precursor peptide (PatE) of approximately 35 to 50 residues in length. Amino acid recognition sequences that flank a core sequence within PatE are recognized

^aDepartment of Chemistry, Queen's University, 90 Bader Lane, Kingston, Ontario, K7L 3N6, Canada. E-mail: dlzechel@chem.queensu.ca; Tel: +1-613-533-3259

^bPharmaceutical Biology and Biotechnology, Institute of Pharmaceutical Sciences, Albert-Ludwigs University, Freiburg, Germany

^cInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

† Electronic supplementary information (ESI) available: NMR spectroscopic data for curacozole; bacterial strains and plasmids; supplementary MS data for enzyme reactions; structural sequence alignments; PDB files for AlphaFold predicted structures; experimental methods for mutagenesis of curacozole BGC, cultivation of bacteria, expression and purification of proteins, enzyme activity assays, LC-MS methods. See DOI: <https://doi.org/10.1039/d4sc02262a>

‡ These authors contributed equally to this work.






Fig. 1 Curacozole and related cyanobactin-like molecules. (A) Structures of curacozole and sub-family relatives. (B) Comparison of the predicted biosynthetic gene clusters encoding curacozole (*czl*), aurantizolicin (*aur*), and YM-216391 (*ym*), mechercharstatin (*mcm*), and telomestatin (*tls*). Conserved genes share a common color. Predicted functions are shown in the legend. (C) Amino acid sequences of the precursor peptides CzlA, AurA, YmA, and McmA. The core peptide sequences are highlighted in yellow.

by PatD, an ATP-dependent cyclodehydratase of the YcaO superfamily,¹⁷ which catalyzes the formation of oxazoline and thiazoline rings from Ser/Thr and Cys side chains, respectively, within the core sequence. The precursor peptide is then cleaved on each side of the modified core sequence by a pair of serine-dependent proteases. One protease, Pata, cleaves on the N-terminal side of the core sequence, followed by the second protease PatG on the C-terminal side. However, unlike PatA, PatG functions as a macrocyclase by capturing the peptidyl-acyl-serine intermediate with the N-terminus of the peptide, resulting in N- to C-macrocyclization rather than hydrolysis. The macrocycle can then undergo dehydrogenation by a flavin mononucleotide (FMN)-dependent oxidase to produce oxazole and thiazole rings. In the case of patellamide biosynthesis, the FMN oxidase is present as a fusion with the macrocyclase PatG; however, there are examples of stand-alone oxidases, such as ThcOx, that will convert azolines to azoles.^{3,18,19}

The conserved BGCs encoding **1**, **2**, and **3** deviate significantly from canonical cyanobactins such as trunkamides and patellamides, despite featuring similar macrocyclic structures and multiple heterocycles.¹⁷ While the *czl*, *aur*, and *ym* clusters all contain a gene encoding the cyclodehydratase YcaO (*czlD* for **1**), they do not contain conserved genes encoding proteases or macrocyclases which typify the cyanobactin class of RiPPs.¹⁷ Likewise, the sequences *czlE*, B1, BC, C1, I, and F have no homologs in the *tru/pat* BGCs. Finally, while spontaneous epimerization of amino acid side chains is thought to occur in

RiPPs when the corresponding α -carbon is adjacent to a thiazole or oxazole, presumably through resonance stabilization of an α -carbanion,^{3,20} such a mechanism is not possible to account for the formation of the *D-allo*-Ile residue in **1**, where the α -carbon is not directly adjacent to such moieties. Intriguingly, the recently reported BGC for mechercharstatin 5 (*mcm*)²¹ appears to be a hybrid of the telomestatin 6 (*tls*)²² and *czl/ym/aur* BGCs (Fig. 1B). Most notably, the genes *mcmG* and *mcmH* encode proteases homologous to *tlsS* and *tlsT* that are proposed to mediate cleavage of the flanking peptide sequences and N- to C-terminal peptide macrocyclization. In contrast, *mcmE*, *mcmF*, and *mcmI* encode homologs of *czlB1*, *czlC1*, and *czlE*, respectively, which are conserved in the *czl/ym/aur* BGCs (Table S3†). Finally, the *czlF* gene (which is distinct from *mcmF*) is unique to the *czl/ym/aur* clusters. Overall, while these studies provide some insight into the biosynthesis of **1**, a minimal BGC for **1** biosynthesis has not been defined, nor have functions been demonstrated for the conserved genes of the *czl/ym/aur* BGCs.

Inspired by the unique features of the BGC encoding **1**, we investigated several key aspects of the biosynthesis of this molecule, including activation of the production of **1**, definition of the minimal biosynthetic gene cluster, processing of precursor peptide variants, and reconstitution of reactions with purified enzymes. Overall, these studies expand the impressive repertoire of RiPP biosynthetic reactions and form a basis for further investigations of enzyme function in the biosynthesis of **1** and pathway engineering.

Results

Production of curacozole by *S. curacoi* is dependent on the *bldA*-specified Leu-tRNA^{UUA}

We have previously demonstrated that constitutive expression of *bldA* in *Streptomyces*, even those with functional *bldA* sequences, can activate cryptic BGCs and alter secondary metabolite profiles.²³ This includes *S. curacoi* DSM40107. A compound **1** with a molecular ion $m/z = 741$ ($[M + H]^+$) had been observed previously in liquid cultures of *S. curacoi*/pTESa-*bldA*, a strain expressing a copy of *bldA* from the *ermE** promoter in the integrative plasmid pTESa.²³ Here we confirm that **1** corresponds to curacozole. It is also observed that *bldA* influences production of **1** by *S. curacoi* when grown on solid media. Culture extracts from *S. curacoi*/pTESa-*bldA* grown on mannitol soya agar were resolved by UPLC-DAD-MS, showing production of compound **1** (Fig. 2B). In contrast, **1** is not observed in cultures of the control strain *S. curacoi*/pTESa (Fig. 2A). Interestingly, production of **1** by *S. curacoi*/pTESa-*bldA* in liquid culture is highly sensitive to conditions that promote dispersed growth. Specifically, production of **1** is observed in shake flasks containing metal springs, which promote dispersed growth (Fig. 2D), but not in flasks lacking springs (Fig. 2C). Compound **1** was purified from a 6 L liquid culture of *S. curacoi*/pTESa-*bldA* through a sequence of solid-phase extraction, reverse phase (C₁₈), and silica gel chromatography, yielding 251 mg of curacozole (42 mg L⁻¹ culture purified yield). Data obtained from high-resolution MSⁿ and multidimensional NMR spectroscopy is consistent with previously reported characterization for curacozole (Tables S1 and S2, Fig. S2 to S4†).^{1,11} The effect of *bldA* on production of **1** is notable because the native sequence of *bldA* on the *S. curacoi* chromosome (accession NZ_KQ947984.1) is predicted to encode a correctly folded

Leu-tRNA^{UUA} molecule (Fig. S1B†). Also attesting to the functionality of the native *bldA* gene is the ability of the wild-type strain to produce abundant spores when grown on solid media (Fig. S1A†). Additionally, the effect of *bldA* on expression of the *czl* BGC appears to be indirect, as no genes within the *czl* BGC contain TTA codons. The flanking *czlK* sequence contains a single TTA codon, specifying Leu47 of the encoded enzyme. However, as shown below, *czlK* is not necessary for biosynthesis of **1**.

Definition and mutagenesis of a minimal curacozole BGC

A sequence of approximately 11 kbp spanning the putative BGC for **1** (genes *czlI* through *czlK*) was PCR amplified from *S. curacoi* genomic DNA and cloned into the integrative plasmid pTESa, yielding pTESa-*czl* (Tables S4 and S5†). Plasmid pTESa-*czl* was introduced into *S. coelicolor* CH999 *via* intergeneric conjugation. Cultivation of *S. coelicolor*/pTESa-*czl* in liquid media followed by LC-MS analysis of a culture extract revealed a peak with the same retention time and m/z value (741, $[M + H]^+$) as **1** produced by *S. curacoi*/pTESa-*bldA* (Fig. 3, I and II). No such peak is observed in the control strain containing the empty plasmid, *S. coelicolor*/pTESa (Fig. 3, III). To further refine the boundaries of the *czl* BGC, the flanking genes *czlI*, *czlJ*, and *czlK* were deleted from pTESa-*czl*. The gene *czlI*, which is conserved in the *ym* and *aur* BGCs, is predicted to encode an enzyme of the cupin superfamily and resides immediately upstream of the pre-peptide gene *czlA*. LC-MS analysis of extracts from *S. coelicolor*/pTESa-*czlΔI* revealed continued production of **1** (Fig. 3, IV), indicating that *czlI* is not essential for biosynthesis. *CzlK* and *czlJ*, encoding a serine hydrolase and a protein of unknown function, respectively, appear at the opposite end of the *czl* cluster relative to *czlI* and are not conserved in the *ym* and *aur*




Fig. 2 Curacozole production in *S. curacoi* is sensitive to *bldA* expression and cultivation conditions. (A) UPLC chromatogram ($\lambda = 300$ nm) of an extract from *S. curacoi*/pTESa grown on MS-agar. (B) Corresponding extract from *S. curacoi*/pTESa-*bldA*. The curacozole peak is labelled as **1**. (C) Extract from *S. curacoi*/pTESa-*bldA* grown in liquid culture without metal springs in the shake flask for dispersed growth (D). Extract from *S. curacoi*/pTESa-*bldA* grown in liquid culture with metal springs.






Fig. 3 (A) Mutational analysis of the curacozole BGC in *S. curacoi-bldA* and the heterologous host *S. coelicolor*/pTESa-czl. Normalized extracted-ion chromatograms for $m/z = 740$ –742 corresponding to curacozole are shown. (B) Extracted ion chromatograms for heterologously produced Czla variants yielding curacozole derivatives. Observed m/z values are indicated for the numbered peak in each chromatogram. *S. lividans* Δ YA9 was used to produce 7 and 9, while *S. coelicolor* CH999 was used to produce 8, 10, 2, and 11.

BGCs. Production of **1** is also observed in the culture extract of *S. coelicolor*/pTESa-czl Δ JK (Fig. 3, V), indicating that *czlJ* and *czlK* are not necessary for biosynthesis. In contrast, deletion of *czlD*, *czlC1*, *czlF*, and *czlBC* in *S. coelicolor*/pTESa-czl led to loss of production of **1** (Fig. 3, VI to IX), as did disruption of *czlE* and *czlB1* in *S. curacoi-bldA* (Fig. 3, X and XI). These experiments demonstrate that the minimum BGC for biosynthesis of **1** consists of the seven genes: *czlA*, D, E, B1, C1, F, and BC.

The substrate flexibility of the biosynthetic pathway leading to **1** was examined by expressing variants of the precursor peptide Czla. Mutant *czlA* sequences encoding substitutions

within the core peptide sequence FIIGSTCC_{18–26} were introduced into pTESa-czl, which in turn was transformed into *S. coelicolor* CH999 and *S. lividans* Δ YA9. Six Czla variants with core peptide sequences WIIGSTCC, YIIGSTCC, FILGSTCC, FIVGSTCC, FIIGSSCC and FIIGSSSC (substituted residues underlined) were successfully processed by the pathway to form the expected curacozole derivatives **7**, **8**, **9**, **10**, **2**, and **11**, as detected by LC-MS analysis of culture extracts (Fig. 3B). It is notable that while Czla F18W and F18Y variants are successfully processed by the pathway, yielding indole and 4-hydroxyphenylloxazole derivatives **7** and **8**, the Czla F18V variant did

not yield a product (data not shown). Therefore, the presence of an aromatic amino acid at position 18 in the CzlA sequence appears to be essential for full pathway processing.

Co-dependent cyclodehydratase and dehydrogenase activities of CzlD and CzlBC

The *czlD* sequence encodes a hypothetical YeaO family cyclodehydratase,¹⁷ while *czlBC* encodes a hypothetical E1-like/dehydrogenase fusion enzyme (Table S3†). It has been hypothesized that CzlD will form the oxazoline/thiazoline rings of curacozole, followed by oxidation by CzlBC to form the final oxazole/thiazole moieties.^{7,13} To assign specific functions to these enzymes, we first modelled the structures of CzlD and CzlBC using AlphaFold2.²⁴ The top ranked models were submitted to the DALI Server²⁵ to search the Protein Data Bank (PDB) for structural homologs. From the search with CzlD, the top hit was LynD (PDB ID: 4V1V, RMSD = 3.4 Å, Z = 31.8), a YeaO family cyclodehydratase from the aestuamide pathway (Fig. 4A, Fig. S9A and B†).^{26,27} Interestingly, the peptide-binding domain observed in the structure of LynD is not present in CzlD, which consists solely of the catalytic YeaO domain. A comparison of the ATP-binding site of LynD with the CzlD model reveals several conserved residues involved in ATP and Mg²⁺ binding (Fig. 4A, Fig. S9C and S10†). The binding of the precursor peptide CzlA to CzlD was also modelled using AlphaFold2 (Fig. S9D and E†).²⁴ This model revealed that the

STCC_{22–56} sequence of CzlA, which are converted to oxazoles and thiazoles in 1, is positioned adjacent to the predicted ATP-binding site of CzlD. This predicted binding mode of CzlA is consistent with the predicted ATP-dependent cyclodehydratase activity of CzlD. To test this prediction, CzlD and CzlA were expressed and purified from *E. coli* (Table S6, Fig. S5 and S6†), then incubated together in the presence of ATP. However, no reaction with CzlA was observed over 24 hours at 25 °C by UPLC-MS analysis (Fig. S13†). This indicates that the CzlD/CzlA model is not representative of a reactive complex.

We next examined the model of the putative dehydrogenase, CzlBC. A DALI²⁵ search of the PDB identified the top structural homolog as ThcOx (PDB ID: 5LQ4; RMSD = 3.8 Å, Z = 24.8).¹⁹ ThcOx is a stand-alone cyanobactin oxidase comprised of an N-terminal, E1-like domain that is predicted to bind the leader sequence of the peptide substrate, and a C-terminal FMN-dependent catalytic domain.^{18,19} CzlBC shares both the peptide-binding and FMN-binding domains of ThcOx, along with several conserved FMN-binding residues (Fig. S9F–H, K and S12†). A complex of the precursor peptide CzlA bound to CzlBC was modelled using AlphaFold2,²⁴ revealing a beta-strand formed by CzlA residues 9–29 bound to the N-terminal E1-like domain of CzlBC (Fig. 4B, S9I and J†). In this model the N-terminal sequence of CzlA (IEEVVDIEVGFI_{9–20}) is predicted to form a β-strand that continues the 2-stranded antiparallel β-sheet of CzlBC's E1-like domain (residues 176–192). This is




Fig. 4 CzlD and CzlBC structure predictions from AlphaFold2 (A and B) and AlphaFold3 (C and D). (A) CzlD (purple) aligned with LynD (PDB ID: 4V1V; RMSD = 3.4 Å, Z = 31.8). The precursor peptide bound to LynD is shown in yellow. Active site residues of LynD and the bound ATP analog ANP are shown as sticks. Metal ions Mg²⁺ and Zn²⁺ are shown as spheres. (B) CzlA (cyan) complexed with CzlBC (yellow). (C) Model of the (CzlD/BC)₂ complex bound to two CzlA peptides. CzlD monomers shown in purple and magenta; CzlBC in yellow and orange; CzlA in cyan and teal. CzlA residues S22, T23, C24, and C25 are shown as sticks. (D) The beta-sheet interaction between CzlA and CzlBC in the (CzlD/BC/A)₂ complex.



followed by a variable loop containing the middle of the core peptide (GS_{21-22}) and then a second, short β -strand (TCCSLEM_{23-29}). Overall, the predicted binding mode of CzlA to the N-terminal E1-domain of CzlBC collectively creates a 4-stranded antiparallel β -sheet (Fig. 4B) which resembles the peptide binding domain architecture of cyclodehydratases such as PatD or LynD.¹⁷ The predicted binding mode places the core peptide sequence of CzlA approximately 30 Å from the FMN co-factor binding site of CzlBC. Therefore, a conformational change in CzlBC or an alternative binding mode for CzlA would be necessary for oxidation to occur, which may be induced by complex formation with CzlD.

Because CzlD alone failed to convert the pre-peptide CzlA (Fig. S13†), the combined activities of CzlD and CzlBC towards CzlA were examined *in vitro*. CzlBC was expressed and purified from *E. coli* (Fig. S7†). A reaction mixture consisting of 5 μM CzlD, 5 μM CzlBC, 50 μM CzlA, 50 μM FMN, 1 mM ATP, 5 mM MgCl₂ (pH 7.5) was incubated at 25 °C for 24 hours. The peptide product was then proteolyzed using endoproteinase GluC to release the CzlA₁₆₋₂₈ sequence encompassing the core peptide then analyzed by UPLC-MS. The calculated mass of CzlA₁₆₋₂₈ is 1327.6152 Da, and the corresponding M + 1 ion at 1328.6 m/z was observed at 6.3 min (Fig. 5A, upper panel). After the reaction, an additional peak at 1308.6 m/z was observed at 6.6 min (Fig. 5A, lower panel). This mass change corresponds to a single

cyclodehydration (−18 Da) and desaturation (−2 Da) of a Ser, Thr, or Cys side chain to form an oxazole or thiazole moiety. Reaction of CzlD and CzlBC with the CzlA variants C24S, C25S, and C24S/C25S also produced a 20 Da mass loss, indicating that heterocyclization was not occurring at either Cys residue (Tables S7 and S8, Fig. S14†). Next, MS/MS based peptide sequencing was used to identify the heterocyclized residue. Reaction products derived from CzlA and CzlA C24S/C25S were treated with GluC to release the CzlA₁₆₋₂₈ sequence. The MS/MS fragmentation spectrum of the CzlA₁₆₋₂₈ sequence indicates that Ser22 in both variants was converted to an oxazole (Fig. 5B and S15†).

The co-dependence of CzlD and CzlBC for heterocyclization of CzlA implies formation of a reactive protein complex. A protein complex consisting of CzlD/BC/A could not be observed by size exclusion chromatography as the individual proteins alone or together eluted with the void volume (data not shown). An AlphaFold3²⁸ model of the CzlD/BC/A complex shows a similar binding mode between CzlD and CzlA, but the β -sheet interaction between CzlA and BC is absent (Fig. S11A and B†). However, as ThcOx¹⁹ is biologically relevant as a homodimer, we surmised that including two copies of CzlBC and CzlD may represent a reactive complex. The AlphaFold3²⁸ prediction of the corresponding (CzlD/BC/A)₂ complex reveals a heterotetramer of CzlD and CzlBC, where two CzlD/BC heterodimers




Fig. 5 Cyclodehydratase CzlD and dehydrogenase CzlBC combine to form an oxazole on Ser22 of CzlA. (A) UPLC-MS analysis of the cyclodehydration and dehydrogenation of CzlA by CzlD and CzlBC, respectively, followed by proteolysis by GluC to produce the CzlA₁₆₋₂₈ sequence. Upper panel shows SIR of CzlA₁₆₋₂₈ at 1328.6 m/z. Lower panel shows 5-channel SIR at 1328.6 m/z and the expected m/z for 4 sequential heterocyclization/oxidation reactions (1308.6, 1288.6, 1268.6, and 1248.6 m/z). (B) MS/MS sequencing. The oxazole-containing CzlA was trimmed with GluC to release the CzlA₁₆₋₂₈ sequence, which was then sequenced by MS/MS fragmentation of the molecular ion (m/z = 1308.6, [M + H]⁺). Ions that deviate by m/z = −20 from the calculated values for the native CzlA sequence are indicated. The modified Ser22 residue is highlighted as a red sphere.



interface through CzI BC (Fig. 4C, S11C and D†). In this model, the N-terminal E1-like domain of CzI BC maintains the β -sheet interaction with the N-terminal leader sequence of CzI A, while the core peptide sequence of CzI A projects into the active site of CzI D (Fig. 4D). Overall, CzI BC is predicted to assist catalysis of CzI D by forming a protein complex as well as by binding the precursor peptide *via* the E1 domain.

CzI is a Fe/2OG dependent dioxygenase that creates a CzI A Phe18Tyr variant

CzI is predicted to specify a metalloenzyme belonging to the JmjC subfamily of cupin enzymes (Table S3†). To investigate the function of CzI, the structure was first predicted using AlphaFold2 (Fig. S16A and B†).²⁴ The top structural homolog identified by DALI²⁵ is *Bacillus subtilis* YxbC, a putative Fe(II) and 2-oxoglutarate (2OG)-dependent dioxygenase (PDB ID: 1VRB, RMSD = 3.3 Å, Z = 23.7). In the active site of CzI, His 145, Asp 147, and His 224 align with the 2 His/1 Asp motif of the YxbC which are used to bind the catalytic Fe(II) ion (Fig. 6A and S17†). Binding of peptide CzI A to CzI was modelled using AlphaFold2.²⁴ In this model, CzI A is observed to bind across the active site with Phe18 positioned next to the predicted site of the catalytic Fe(II) ion (Fig. 6B, C and S16C, D†).

Based on this structural analysis, we predicted that CzI would perform a Fe(II) and 2OG-dependent oxidation reaction on Phe18 of CzI A. To test this hypothesis, CzI was expressed with an N-terminal His₆ tag in *E. coli* and purified to homogeneity by immobilized metal affinity chromatography (Table S6 and Fig. S8†). A reaction mixture consisting of 5 μ M CzI, 50 μ M CzI A, 1 mM 2OG, 100 μ M ammonium iron(II) sulfate, and 200 μ M ascorbic acid (pH 7.5) was incubated at 25 °C for 18 hours. The peptide product was digested with GluC to release CzI A₁₆₋₂₈, followed by UPLC-MS analysis. Compared to unmodified CzI A (Fig. 7A, upper panel), reaction with CzI yields a new peak with 1344.6 m/z (Fig. 7A, lower panel). This corresponding increase in mass by 16 Da is consistent with incorporation of

a single oxygen atom. An equivalent mass change is observed directly on the intact peptide (Fig. S18A†). No change in the mass of CzI A was observed when 2OG was omitted from the reaction (Fig. S18B, Table S9†). Likewise, no mass change was observed when CzI was reacted with the variant CzI A F18G (Fig. S19†), implying Phe18 was the modified residue. Pre-treating CzI A with GluC followed by reaction with CzI showed minimal conversion of the resulting CzI A₁₆₋₂₈ peptide to the hydroxylated product (Fig. S18C†), indicating that the sequences flanking the core peptide of CzI A are also necessary for activity. MS/MS based peptide sequencing of the modified CzI A₁₆₋₂₈ peptide confirmed that Phe18 was the site of oxygen incorporation (Fig. 7B).

We next determined the position of oxygenation on Phe18 of CzI A. Hydroxylated CzI A was subjected to total acid hydrolysis followed by reaction of the liberated amino acids with dansyl chloride. The resulting dansylated amino acids were resolved by UPLC-MS along with dansylated amino acid standards. CzI-modified CzI A produces dansylated Phe (Fig. 7C, I and III) in addition to a new peak that co-elutes with dansylated Tyr (Fig. 7C, II and IV), which was confirmed by spiking the sample with dansylated Tyr and observing an increase in the size of the peak (Fig. S20A and B†). This result is consistent with two Phe residues, Phe2 and Phe18, in the CzI A sequence, with Phe 18 being converted to Tyr. Reaction of CzI A with CzI in the absence of the co-substrate 2OG does not produce the dansylated Tyr peak (Fig. S20C†), which is consistent with the 2OG-dependence of CzI, and the absence of a Tyr residue in the CzI A sequence. Peaks corresponding to dansylated L-meta-Tyr, D/L-ortho-Tyr, and D/L-phenylserine are not observed as products of CzI-modified CzI A (Fig. S21†). Because the pathway for **1** can process the CzI A F18Y variant to form the hydroxylated derivative **8** (Fig. 3B, II), we hypothesized that *S. curacoi-bldA* would also produce this derivative through the activity of CzI. This proved to be the case, whereby the extracted ion chromatogram of the *S. curacoi-bldA* culture extract revealed a peak with the




Fig. 6 Fe/2OG dioxygenase CzI structure predictions from AlphaFold2. (A) CzI (green) aligned with a predicted asparaginyl hydroxylase (PDB ID: 1VRB; RMSD = 3.3 Å, Z = 23.7) shown in tan. Metal ion Fe²⁺ is shown as an orange sphere and water molecules are shown as smaller red spheres. Labelled iron-coordinating residues are shown as sticks. (B) CzI A (cyan) complexed with CzI (green). (C) The putative active site residues of CzI (green) complexed with CzI A (cyan). Metal ion Fe²⁺ is modelled as an orange sphere. Iron-coordinating residues are shown as sticks. Phe18 of CzI A is shown as pink sticks.






Fig. 7 CzII oxidatively converts CzIA to CzIA F18Y. (A) UPLC-MS analysis of the hydroxylation of CzIA by CzII. Upper panel shows SIR of CzIA_{16–28} at 1328.6 m/z , with core peptide sequence shown in parentheses. Lower panel shows SIR of CzIA following reaction with CzII with a smaller peak at 1328.6 m/z and a larger peak at 1344.6 m/z . The m/z value increases from substrate to product by a value that corresponds to addition of oxygen (+16 Da). See Table S9† for calculated and observed masses. (B) MS/MS sequencing of hydroxylated CzIA. The peptide was trimmed with GluC to release the CzIA_{16–28} sequence (shown above), which was then sequenced by MS/MS fragmentation of the molecular ion at 1344.6 m/z ($[M + H]^+$). Ions that deviate by $m/z = +16$ from the calculated values for the native CzIA sequence are indicated. The hydroxylated Phe18 residue is highlighted with a green sphere. (C) UPLC-MS analysis of dansylated amino acids arising from acid hydrolysis of hydroxylated CzIA. The chromatograms show single ion recordings (SIR) for dansylated phenylalanine (DNS-Phe, m/z 399.13) and dansylated tyrosine (DNS-Tyr, m/z 415.12). Chromatograms (I) and (II) correspond to amino acids derived from hydroxylated CzIA, while (III) and (IV) correspond to standards of dansylated Phe and Tyr. Additional SIR chromatograms were recorded for dansylated D/L- and L-phenylserine, L-*meta*-Tyr, and D/L-*ortho*-Tyr (see Fig. S18†). (D) Extracted ion chromatogram (m/z 756–758) of an *S. curacoi*-*bldA* extract. The observed m/z value of the peak corresponding to the hydroxylated derivative **8** formed by the activity of CzII is indicated.

expected m/z value for hydroxylated **8** (Fig. 7D). Overall, these results indicate that CzI oxidatively converts CzIA to form a CzIA F18Y variant, which is ultimately processed by the curacozole pathway to form a hydroxylated curacozole derivative **8**.

Discussion

The *czl* cluster encoding **1** is an interesting example of a cryptic BGC. The *bldA* specified Leu-tRNA^{UUA} molecule is necessary for translating UUA codons, which are rare in *Streptomyces*

genomes and tend to be found in regulatory and biosynthetic genes.²⁹ Mutations in *bldA* have long been shown to disrupt sporulation and secondary metabolite biosynthesis in *Streptomyces*.³⁰ This has led to the hypothesis that *bldA* and TTA codons form a mechanism for regulating the biosynthesis of bioactive molecules in *Streptomyces*.³¹ Constitutive expression of *bldA* in *S. curacoi* and other *Streptomyces* has been shown to activate or enhance production of secondary metabolites, including annimycin and nucleocidin in *S. calvus*,^{23,32} peucymycin in *S. peuetius*,³³ jadomycin in *S. venezuelae*,³⁴ milbemycin A₄ in *Streptomyces* sp. BB47,³⁵ nosokomycin A in *S. ghanaensis* B38.3,³⁶ daunorubicin in *S. peuetius* ATCC 27952,³⁷ and ascamycin in *Streptomyces* sp. 80H647.³⁸ In the case of *S. curacoi*, *bldA* expression has a potent effect on the production of **1**, with levels of **1** rising from below detection limits in the wild-type strain to 42 mg L⁻¹ culture in the *S. curacoi*/pTESa-*bldA* strain. In contrast, 2 mg L⁻¹ culture of **1** was obtained from the rifampicin resistant mutant *S. curacoi* R25 reported by Kaweewan and co-workers.¹ Because yields of cyanobactins and cyanobactin-like compounds are typically poor in native producers, methods such as heterologous expression, optimizing metabolic pathways, and genome engineering have been used to improve titres or produce derivatives, including telomestatin **6** (5 mg L⁻¹),²² patellins (27 mg L⁻¹),³⁹ aurantizolicin **2** (5–10 mg L⁻¹),⁴⁰ and YM-216391 **3** (4–36 mg L⁻¹).^{13,41} The high titre of **1** induced by *bldA* expression in *S. curacoi* is notable in this context and serves as a good starting point for pathway engineering.

The minimum BGC encoding **1** has been established through gene deletion and heterologous expression studies as the seven genes *czlA*, *D*, *E*, *B1*, *C1*, *F*, and *BC*. The flanking genes *czlI*, *czlJ*, and *czlK*, while not essential, may play a regulatory or auxiliary role in the biosynthesis of **1** in *S. curacoi*, which is bypassed through heterologous expression of the seven essential genes from the strong constitutive promoter, *ermE**. Interestingly, studies by Guo and co-workers have shown that the *ym* BGC encoding **3** is transcribed as an eight-gene cistron (*ymI* to *ymBC*) under the control of a single promoter, likely that of *ymI* (equivalent to *czlI*).⁴² *In vitro* studies have now assigned functions to *CzlD* (YcaO cyclodehydratase), *CzlBC* (FMN-dependent oxidase), and *CzlI* (peptide-specific Fe/2OG oxygenase). This leaves *CzlE*, *B1*, *C1*, and *F* with experimentally undefined roles. In the pathway for **5**, deletion of *mcmE*, the homolog of *czlB1*, abolishes production of **5** and instead yields an interesting macrocycle that is larger by two amino acids and retains the phenylserine.²¹ *CzlB1* is likewise shown to be essential for biosynthesis of **1**. This suggests a role for *CzlB1* and *McmE* as cyclodehydratases to form the phenyloxazole. *CzlE* encodes a predicted P450 monooxygenase, and is thought to add a hydroxyl group to the β -carbon of Phe to form a phenylserine residue.^{1,21} As shown here, *czlE* is essential in the biosynthesis of **1**, as is the homolog *mcmI* in the pathway for **5**.²¹ However, the activity of *CzlE* or its homologs has not yet been reconstituted *in vitro*, therefore the details of this reaction remain unknown. *CzlC1* and *czlF* encode proteins of unknown function yet are shown in this work to be essential for production of **1**. While both *czlC1* and *czlF* sequences are conserved in the *ym* and *aur*

BGCs, only *czlC1* has a homolog, *mcmF*, in the BGC for **5**.²¹ Finally, the minimal BGC for **1** is notable for lacking the class-defining cyanobactin biosynthetic genes encoding enzymes that would catalyze proteolysis and macrocyclization to form **1**. Such functions might be encoded by *czlE*, *B1*, or *F*. It is also possible that proteolysis and/or macrocyclization may be carried out by proteases that are endogenous to *Streptomyces*. A similar phenomenon is observed in the biosynthesis of **6**: when *tlsS* and *tlsT*, encoding predicted peptidases (Fig. 1), are deleted, heterologous production of **6** is reduced but not abolished.²²

Heterocyclization of serine, threonine, and cysteine side chains to form oxazoles and thiazoles is a distinctive feature of cyanobactins that is shared by the cyanobactin-like family represented by **1**. The YcaO family cyclodehydratase *CzlD*, in combination with the FMN-dependent oxidase *CzlBC*, is shown to convert Ser22 of the precursor peptide *CzlA* into an oxazole. This is the first residue of the *CzlA* STCC_{22–25} sequence that yields a sequence of oxazole–methyloxazole–thiazole–thiazole in **1**. In contrast, *TruD* has been shown to form heterocycles starting with the most C-terminal residue (in this case Cys) of the core sequence of the peptide substrate.⁴³ *CzlD* and *CzlBC* also convert Ser22 to an oxazole when the Cys residues of the STCC_{22–25} sequence are substituted for Ser. However, in all cases, additional heterocycles are not formed by *CzlD* and *CzlBC*. This may stem from the requirement of other modifications to occur on *CzlA* before other heterocycles can be formed. Notably, heterocyclization operates by a specific order in the biosynthesis of **5**, where the first three heterocycles are not formed by *McmB/C/D1* on the precursor peptide until the dehydroalanine residue is created.¹⁷

CzlD was unable to form an oxazoline on *CzlA* in the absence of *CzlBC*, suggesting that *CzlBC* is providing a required function. The predicted structure for *CzlD* lacks an E1-like peptide-binding domain that is observed in other YcaO enzymes such as *LynD* or *PatD*.¹⁷ In these enzymes, the E1 domain engages the peptide substrate while the YcaO domain catalyzes ATP-dependent backbone amide activation and heterocyclization.^{3,44} The AlphaFold2 model for *CzlD* predicts binding of the core peptide sequence of *CzlA* within the ATP-binding site. However, the AlphaFold2 model for *CzlA* bound to *CzlBC* shows the leader peptide of the former continuing the β -sheet topology of the E1-like “C” domain of the latter. This resembles the binding mode of a precursor peptide substrate to the aestuaramide cyclodehydratase *LynD*, where the leader peptide binds to and extends the 3-stranded β -sheet of the E1-like domain to create a 4-stranded anti-parallel β -sheet.²⁶ However, an AlphaFold3 model of (CzlD/BC/A)₂ complex combines these interactions, with *CzlBC* binding the leader sequence of *CzlA*, while the core peptide sequence of the latter is bound to the active site of *CzlD*. Therefore, it is possible that *CzlD* requires *CzlBC* for recruitment of the *CzlA* peptide for processing. Interestingly, in the pathway for **5**, the oxidase “B” and E1-like “C” components occur as separate proteins.²¹

CzlI is shown to be a Fe/2OG dependent dioxygenase, and the first example of a phenylalanine-specific peptide hydroxylase.⁴⁵ Out of two possible Phe residues in the *CzlA* substrate, only Phe18 is converted to Tyr. The corresponding *CzlA* F18Y



product is processed by the pathway to form a new curacozole derivative **8** with a *p*-hydroxyphenyloxazole group. Furthermore, the production of **8** through the activity of CzII was confirmed in *S. curacoi*-*bldA* culture extracts. The activity CzII as a peptide hydroxylase is also dependent on the sequences that flank the core peptide of CzIA, as shown by minimal conversion of a truncated CzIA_{16–28} sequence. Fe/2OG-dependent dioxygenases are commonly found as tailoring enzymes in biosynthetic pathways and in the post-translational modification of proteins.^{46–48} CzII belongs to the Jumonji-C (JmjC) subfamily of Fe/2OG oxygenases, which includes enzymes that hydroxylate amino acid residues of proteins (e.g.: Lys, His, Asn, Asp), as well as demethylate *N*-methylated Lys and Arg residues of various protein targets, such as histones, as a mechanism of epigenetic regulation.^{49,50} CzII also joins a small but emerging group of Fe/2OG enzymes acting on peptides during RiPP biosynthesis, including CinX (β -hydroxylation of Asp in cinnamycin),⁵¹ ThoJ and TsajJ (β -hydroxylation of dimethyl-His in thioholgamide and thiostreptamide S4),⁵² and CanE (β -hydroxylation of Asp in canucin A).⁵³ Interestingly, a predicted P450 monooxygenase, TaaCYP, is proposed to generate an *ortho*-tyrosine residue in thioalbamide.⁵⁴ Analogous to these examples, CzII serves as a tailoring enzyme to enhance the structural diversity of products that are generated by the pathway.

Conclusions

Curacozole is representative of an outlying group of cyanobactin-like molecules that deviate biosynthetically from canonical cyanobactins such as patellamides and trunkamides. A minimal biosynthetic gene cluster has been determined for the biosynthesis of curacozole consisting of seven genes, *czlA*, *D*, *E*, *B1*, *C1*, *F*, and *BC*. The expression of this BGC is cryptic in the host strain *Streptomyces curacoi*, and shows a dramatic dependence on the *bldA* gene, encoding a rare Leu-tRNA^{UUA} molecule. The high titre of curacozole produced in *S. curacoi* upon constitutive *bldA* expression, in addition to the tolerance of the pathway to substitutions in the core peptide sequence of precursor peptide CzIA, make this a promising system for producing curacozole derivatives with new bioactivities. Knowledge of the minimal curacozole BGC also sets the stage for functional analysis of the encoded enzymes and defining a biosynthetic pathway. To this end, two early steps in the biosynthesis of **1** and derivatives have been established. The cyclodehydratase CzID, in combination with the FMN-dependent oxidase CzIBC, create a single oxazole on the precursor peptide CzIA from Ser22, while the Fe/2OG-dependent dioxygenase CzII initiates the biosynthesis of a derivative of **1** by hydroxylating Phe18 of CzIA to form a CzIA F18Y variant. The timing and enzymes required to perform the subsequent transformations on CzIA, such as epimerization of Ile19, β -hydroxylation of Phe18, formation of two additional oxazoles and two thiazoles, and macrocyclization, remain to be determined. For this reason, the curacozole biosynthetic pathway has more to contribute to the rich repertoire of RiPP biosynthetic enzymes.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. The figures and tables supporting this article have been uploaded as part of the ESI.†

Author contributions

DLZ and AB conceived of the study and designed experiments. SH, DSS, and IB performed biochemical assays. AG and DSS characterized the cryptic behaviour of curacozole. DSS isolated and characterized curacozole. JT and DW performed gene knock out and heterologous expression studies. DLZ, AB, SH, and JT analyzed the results and wrote the manuscript.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

We are greatly indebted to the late Dr Françoise Sauriol for her assistance with the NMR spectroscopic characterization of curacozole. This work is supported by the Natural Sciences and Engineering Research Council of Canada and by the University of Freiburg.

References

- 1 I. Kaweewan, H. Komaki, H. Hemmi, K. Hoshino, T. Hosaka, G. Isokawa, T. Oyoshi and S. Kodani, *J. Antibiot.*, 2019, **72**, 1–7.
- 2 P. G. Arnison, M. J. Bibb, G. Bierbaum, A. A. Bowers, T. S. Bugni, G. Bulaj, J. A. Camarero, D. J. Campopiano, G. L. Challis, J. Clardy, P. D. Cotter, D. J. Craik, M. Dawson, E. Dittmann, S. Donadio, P. C. Dorrestein, K.-D. Entian, M. A. Fischbach, J. S. Garavelli, U. Göransson, C. W. Gruber, D. H. Haft, T. K. Hemscheidt, C. Hertweck, C. Hill, A. R. Horswill, M. Jaspars, W. L. Kelly, J. P. Klinman, O. P. Kuipers, A. J. Link, W. Liu, M. A. Marahiel, D. A. Mitchell, G. N. Moll, B. S. Moore, R. Müller, S. K. Nair, I. F. Nes, G. E. Norris, B. M. Olivera, H. Onaka, M. L. Patchett, J. Piel, M. J. T. Reaney, S. Rebuffat, R. P. Ross, H.-G. Sahl, E. W. Schmidt, M. E. Selsted, K. Severinov, B. Shen, K. Sivonen, L. Smith, T. Stein, R. D. Süssmuth, J. R. Tagg, G.-L. Tang, A. W. Truman, J. C. Vedera, C. T. Walsh, J. D. Walton, S. C. Wenzel, J. M. Willey and W. A. van der Donk, *Nat. Prod. Rep.*, 2013, **30**, 108–160.
- 3 W. Gu, S.-H. Dong, S. Sarkar, S. K. Nair and E. W. Schmidt, *Methods Enzymol.*, 2018, **604**, 113–163.
- 4 J. Martins and V. Vasconcelos, *Mar. Drugs*, 2015, **13**, 6910–6946.
- 5 G. Zhong, Z.-J. Wang, F. Yan, Y. Zhang and L. Huo, *ACS Bio Med Chem Au*, 2023, **3**, 1–31.

6 M. A. Skinnider, C. W. Johnston, R. E. Edgar, C. A. Dejong, N. J. Merwin, P. N. Rees and N. A. Magarvey, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, E6343–E6351.

7 K. Sohda, K. Nagai, T. Yamori, K. Suzuki and A. Tanaka, *J. Antibiot.*, 2005, **58**, 27–31.

8 Y. Matsuo, K. Kanoh, T. Yamori, H. Kasai, A. Katsuta, K. Adachi, K. Shin-ya and Y. Shizuri, *J. Antibiot.*, 2007, **60**, 251–255.

9 K. Kanoh, Y. Matsuo, K. Adachi, H. Imagawa, M. Nishizawa and Y. Shizuri, *J. Antibiot.*, 2005, **58**, 289–292.

10 K. Kanoh, Y. Matsuo, K. Adachi, H. Imagawa, M. Nishizawa and Y. Shizuri, *J. Antibiot.*, 2007, **60**, C2.

11 A. Oberheide, S. Pflanze, P. Stallforth and H.-D. Arndt, *Org. Lett.*, 2019, **21**, 729–732.

12 K. Shin-ya, K. Wierzba, K. Matsuo, T. Ohtani, Y. Yamada, K. Furihata, Y. Hayakawa and H. Seto, *J. Am. Chem. Soc.*, 2001, **123**, 1262–1263.

13 X.-H. Jian, H.-X. Pan, T.-T. Ning, Y.-Y. Shi, Y.-S. Chen, Y. Li, X.-W. Zeng, J. Xu and G.-L. Tang, *ACS Chem. Biol.*, 2012, **7**, 646–651.

14 E. W. Schmidt, J. T. Nelson, D. A. Rasko, S. Sudek, J. A. Eisen, M. G. Haygood and J. Ravel, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 7315–7320.

15 J. Koehnke, A. F. Bent, W. E. Houssen, G. Mann, M. Jaspars and J. H. Naismith, *Curr. Opin. Struct. Biol.*, 2014, **29**, 112–121.

16 C. M. Czekster, Y. Ge and J. H. Naismith, *Curr. Opin. Chem. Biol.*, 2016, **35**, 80–88.

17 B. J. Burkhart, C. J. Schwalen, G. Mann, J. H. Naismith and D. A. Mitchell, *Chem. Rev.*, 2017, **117**, 5389–5456.

18 W. E. Houssen, A. F. Bent, A. R. McEwan, N. Pieiller, J. Tabudravu, J. Koehnke, G. Mann, R. I. Adaba, L. Thomas, U. W. Hawas, H. Liu, U. Schwarz-Linek, M. C. M. Smith, J. H. Naismith and M. Jaspars, *Angew. Chem., Int. Ed.*, 2014, **53**, 14171–14174.

19 A. F. Bent, G. Mann, W. E. Houssen, V. Mykhaylyk, R. Duman, L. Thomas, M. Jaspars, A. Wagner and J. H. Naismith, *Acta Crystallogr., Sect. D: Struct. Biol.*, 2016, **72**, 1174–1180.

20 B. F. Milne, P. F. Long, A. Starcevic, D. Hranueli and M. Jaspars, *Org. Biomol. Chem.*, 2006, **4**, 631–638.

21 Z.-F. Pei, M.-J. Yang, K. Zhang, X.-H. Jian and G.-L. Tang, *Cell Chem. Biol.*, 2022, **29**, 650–659.e5.

22 K. Amagai, H. Ikeda, J. Hashimoto, I. Kozone, M. Izumikawa, F. Kudo, T. Eguchi, T. Nakamura, H. Osada, S. Takahashi and K. Shin-ya, *Sci. Rep.*, 2017, **7**, 3382.

23 A. Gessner, T. Heitzler, S. Zhang, C. Klaus, R. Murillo, H. Zhao, S. Vanner, D. L. Zechel and A. Bechthold, *ChemBioChem*, 2015, **16**, 2244–2252.

24 M. Mirdita, K. Schütze, Y. Moriwaki, L. Heo, S. Ovchinnikov and M. Steinegger, *Nat. Methods*, 2022, **19**, 679–682.

25 L. Holm, *Nucleic Acids Res.*, 2022, **50**, W210–W215.

26 J. Koehnke, G. Mann, A. F. Bent, H. Ludewig, S. Shirran, C. Botting, T. Lebl, W. E. Houssen, M. Jaspars and J. H. Naismith, *Nat. Chem. Biol.*, 2015, **11**, 558–563.

27 J. A. McIntosh, Z. Lin, M. D. Tianero and E. W. Schmidt, *ACS Chem. Biol.*, 2013, **8**, 877–883.

28 J. Abramson, J. Adler, J. Dunger, R. Evans, T. Green, A. Pritzel, O. Ronneberger, L. Willmore, A. J. Ballard, J. Bambrick, S. W. Bodenstein, D. A. Evans, C.-C. Hung, M. O'Neill, D. Reiman, K. Tunyasuvunakool, Z. Wu, A. Žemgulytė, E. Arvaniti, C. Beattie, O. Bertolli, A. Bridgland, A. Cherepanov, M. Congreve, A. I. Cowen-Rivers, A. Cowie, M. Figurnov, F. B. Fuchs, H. Gladman, R. Jain, Y. A. Khan, C. M. R. Low, K. Perlin, A. Potapenko, P. Savy, S. Singh, A. Stecula, A. Thillaisundaram, C. Tong, S. Yakneen, E. D. Zhong, M. Zielinski, A. Žídek, V. Bapst, P. Kohli, M. Jaderberg, D. Hassabis and J. M. Jumper, *Nature*, 2024, **630**, 493–500.

29 N. Zaburanny, B. Ostash and V. Fedorenko, *Bioinformatics*, 2009, **25**, 2432–2433.

30 O. Tsypik, R. Makitrynskyy, X. Yan, H.-G. Koch, T. Paululat and A. Bechthold, *Microorganisms*, 2021, **9**, 374.

31 K. F. Chater and G. Chandra, *J. Microbiol.*, 2008, **46**, 1–11.

32 L. Kalan, A. Gessner, M. N. Thaker, N. Waglechner, X. Zhu, A. Szawiola, A. Bechthold, G. D. Wright and D. L. Zechel, *Chem. Biol.*, 2013, **20**, 1214–1224.

33 R. T. Magar, V. T. T. Pham, P. B. Poudel, A. F. Bridget and J. K. Sohng, *Appl. Microbiol. Biotechnol.*, 2024, **108**, 107.

34 S. Qiu, B. Yang, Z. Li, S. Li, H. Yan, Z. Xin, J. Liu, X. Zhao, L. Zhang, W. Xiang and W. Wang, *Metab. Eng.*, 2024, **81**, 210–226.

35 N. Matsui, S. Kawakami, D. Hamamoto, S. Nohara, R. Sunada, W. Panbangred, Y. Igarashi, T. Nihira and S. Kitani, *J. Gen. Appl. Microbiol.*, 2021, **67**, 240–247.

36 Y. Kuzhyk, M. Lopatniuk, A. Luzhetskyy, V. Fedorenko and B. Ostash, *Indian J. Microbiol.*, 2019, **59**, 109–111.

37 A. R. Pokhrel, A. K. Chaudhary, H. T. Nguyen, D. Dhakal, T. T. Le, A. Shrestha, K. Liou and J. K. Sohng, *Microbiol. Res.*, 2016, **192**, 96–102.

38 Y. Zheng, N. Morita, H. Takagi, Y. Shiozaki-Sato, J. Ishikawa, K. Shin-ya and S. Takahashi, *ACS Catal.*, 2024, **14**, 3533–3542.

39 Ma. D. Tianero, E. Pierce, S. Raghuraman, D. Sardar, J. A. McIntosh, J. R. Heemstra, Z. Schonrock, B. C. Covington, J. A. Maschek, J. E. Cox, B. O. Bachmann, B. M. Olivera, D. E. Ruffner and E. W. Schmidt, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 1772–1777.

40 Z.-F. Pei, M.-J. Yang, L. Li, X.-H. Jian, Y. Yin, D. Li, H.-X. Pan, Y. Lu, W. Jiang and G.-L. Tang, *Org. Biomol. Chem.*, 2018, **16**, 9373–9376.

41 L. Li, G. Zheng, J. Chen, M. Ge, W. Jiang and Y. Lu, *Metab. Eng.*, 2017, **40**, 80–92.

42 W. Guo, Z. Xiao, T. Huang, K. Zhang, H.-X. Pan, G.-L. Tang, Z. Deng, R. Liang and S. Lin, *Microb. Cell Fact.*, 2023, **22**, 127.

43 J. Koehnke, A. F. Bent, D. Zollman, K. Smith, W. E. Houssen, X. Zhu, G. Mann, T. Lebl, R. Scharff, S. Shirran, C. H. Botting, M. Jaspars, U. Schwarz-Linek and J. H. Naismith, *Angew. Chem., Int. Ed.*, 2013, **52**, 13991–13996.

44 K. L. Dunbar, J. O. Melby and D. A. Mitchell, *Nat. Chem. Biol.*, 2012, **8**, 569–575.

45 A. K. Alexander and S. I. Elshahawi, *ChemBioChem*, 2023, **24**, e202300372.



46 M. S. Islam, T. M. Leissing, R. Chowdhury, R. J. Hopkinson and C. J. Schofield, *Annu. Rev. Biochem.*, 2018, **87**, 585–620.

47 S.-S. Gao, N. Naowarojna, R. Cheng, X. Liu and P. Liu, *Nat. Prod. Rep.*, 2018, **35**, 792–837.

48 C. Q. Herr and R. P. Hausinger, *Trends Biochem. Sci.*, 2018, **43**, 517–532.

49 S. Markolovic, S. E. Wilkins and C. J. Schofield, *J. Biol. Chem.*, 2015, **290**, 20712–20722.

50 S. Markolovic, T. M. Leissing, R. Chowdhury, S. E. Wilkins, X. Lu and C. J. Schofield, *Curr. Opin. Struct. Biol.*, 2016, **41**, 62–72.

51 A. Ökesli, L. E. Cooper, E. J. Fogle and W. A. van der Donk, *J. Am. Chem. Soc.*, 2011, **133**, 13753–13760.

52 T. H. Eyles, N. M. Vior, R. Lacret and A. W. Truman, *Chem. Sci.*, 2021, **12**, 7138–7150.

53 C. Zhang and M. R. Seyedsayamdost, *ACS Chem. Biol.*, 2020, **15**, 890–894.

54 L. Frattaruolo, R. Lacret, A. R. Cappello and A. W. Truman, *ACS Chem. Biol.*, 2017, **12**, 2815–2822.

